Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Jul:29 Suppl 3:77-81.

Clinical assessment of antihistamines in rhinitis

Affiliations
  • PMID: 10444218
Review

Clinical assessment of antihistamines in rhinitis

G K Scadding. Clin Exp Allergy. 1999 Jul.

Abstract

The first line of treatment for allergic rhinitis must be identification and avoidance as far as possible of the relevant allergens. This is rarely completely successful and so pharmaceutical treatment is also needed. Antihistamines are effective in allergic rhinitis, which comprises approximately 80% of rhinitis found in children and 30% in adults. Antihistamines antagonize the effect of histamine at the H1 receptor and their major clinical effects are related to this. They are effective against rhinorrhoea, itch and sneezing but have little effect on nasal obstruction. Clinical trials show between 36% and 80% of patients experiencing good to excellent symptom relief (approximately twice that induced by placebo), in seasonal allergic rhinitis; between 55% and 86% of patients experience moderate to excellent symptom relief in perennial allergic rhinitis. Meta-analysis reveals that antihistamines are inferior to corticosteroids in allergic rhinitis therapy. Antihistamines are generally well tolerated, although serious cardiac dysrhythmias have occurred with terfenadine and astemizole. Their place in therapy is probably as sole agent in mild, intermittent rhinitis and in combination with topical corticosteroids in more severe disease not controlled by corticosteroids alone.

PubMed Disclaimer

MeSH terms

Substances

LinkOut - more resources